Therapeutic area

Gastrointestinal disorders

1 135 clinical trials
479 recruiting
476 conditions
28 countries

Clinical trials in Gastrointestinal disorders

1 135 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

1 135 clinical trials

Sjogren's syndrome

Recruiting

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Telitacicept
Sponsor:Vor Biopharma Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Atebimetinib
Sponsor:Immuneering Corp.

Contact Research Centre

Sjogren's syndrome

Recruiting

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Colitis ulcerative

Recruiting

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational

Czechia

Participants:0–17 years · 18–64 years · 65+ years
Substances:MH002
Sponsor:Microbial Resource Management Health

Contact Research Centre

Colitis ulcerative

Recruiting

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational

Croatia

Participants:18–64 years · 65+ years
Substances:LY4268989 adipic acid
Sponsor:Eli Lilly & Co.

Contact Research Centre

Systemic scleroderma

Recruiting

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Nemolizumab
Sponsor:Galderma S.A.

Contact Research Centre

Colitis ulcerative

Recruiting

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:SPY001-001
Sponsor:Spyre Therapeutics Inc.

Contact Research Centre

Crohn's disease

Recruiting

Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

Registered drugNo placebo

Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo

Austria

Participants:18–64 years
Substances:Bevacizumab
Sponsor:Amgen Inc.

Contact Research Centre

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

Austria

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational

Austria

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Colitis ulcerative

Recruiting

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:SPY001-001
Sponsor:Spyre Therapeutics Inc.

Contact Research Centre

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil208 clinical trials Oxaliplatin200 clinical trials Capecitabine109 clinical trials Folinic Acid84 clinical trials Bevacizumab71 clinical trials Calcium Folinate68 clinical trials Pembrolizumab60 clinical trials Irinotecan Hydrochloride Trihydrate52 clinical trials Paclitaxel50 clinical trials

Gastrointestinal disorders

Conditions in this area

Clinical trials in Gastrointestinal disorders

1 135 clinical trials

Sjogren's syndrome

Phase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease

Pancreatic carcinoma metastatic

Phase 3 Study of atebimetinib with gemcitabine and paclitaxel versus gemcitabine and paclitaxel in patients with metastatic pancreatic cancer

Sjogren's syndrome

Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

Colitis ulcerative

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Colitis ulcerative

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Systemic scleroderma

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Colitis ulcerative

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Crohn's disease

Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

Colorectal cancer metastatic

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Crohn's disease

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Crohn's disease

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Colitis ulcerative

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Filter the trials

Substances studied in this area

Prefer not to search on your own, or looking for clinical trials for a rare disease?